Keyword: Neurocrine

Last May, Neurocrine’s Ingrezza failed a Tourette syndrome trial, prompting the company to design a new one. But the drug has failed that trial, too.

In the tardive dyskinesia market, doctors initially preferred Neurocrine’s Ingrezza over Teva’s Austedo. But that edge is weakening, one analyst says.

A physician survey suggests new drugs to treat tardive dyskinesia—Neurocrine’s Ingrezza, in particular—may capture sales that beat current expectations.

Downtrodden Teva Wednesday got some good news—and Neurocrine got some company.

Neurocrine’s Ingrezza, fresh off its first FDA approval and aiming for another, just hit a major roadblock.

Neurocrine is out with its price for Ingrezza—and it’s even higher than some industry watchers expected.

Take a look at this year’s new drug approval announcements, and you may notice a pattern emerging.

The tardive dyskinesia market race is officially on—and it’s Neurocrine that has the go-ahead to kick things off.

Only 22 meds were greenlighted by the FDA in 2016, but no matter what tally the industry amasses this year, the crop will bring some would-be blockbusters and market disrupters.